Literature DB >> 34371038

Cellular OCIAD2 protein is a proviral factor for hepatitis C virus replication.

Zibing Yang1, Tao Ouyang1, Haruyo Aoyagi2, Ting Wang1, Xiu Xing1, Yanni Zhang3, Yu Wang1, Yihan Li1, Hideki Aizaki4, Sha Li5, Lingbao Kong6.   

Abstract

Hepatitis C virus (HCV) nonstructural protein NS4B is necessary for HCV replication. Our previous research found that NS4B-associated cellular proteins PREB and Surfeit 4 are involved in HCV replication. However, the molecular mechanism of HCV replication is not fully understood. Here we identified cellular ovarian cancer immunoreactive antigen domain containing 2 (OCIAD2) protein as a novel NS4B-associated HCV host cofactor by screening with small interfering RNA. Knockdown of OCIAD2 reduced significantly the HCV replication in a dose-dependent and genotype-independent manner. Further research showed that OCIAD2 was recruited into the HCV RNA replication complex by the interaction with NS4B. Interestingly, HCV replication induced OCIAD2 expression. In turn, overexpression of wild OCIAD2 also promoted virus replication whereas that of OCIAD2 mutant lacking the ability to bind NS4B exerted no effect on HCV replication. We also examined whether OCIAD2 interacted with other proteins participating in the HCV RNA replication complex including viral proteins NS5A, NS5B, and cellular proteins PREB, Surfeit 4. The results showed that OCIAD2 interacted with PREB and NS5A, but not NS5B or Surfeit 4. Our findings provide new insights into the function of OCIAD2 and HCV replication mechanism.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  HCV; NS4B; OCIAD2

Mesh:

Substances:

Year:  2021        PMID: 34371038     DOI: 10.1016/j.ijbiomac.2021.08.032

Source DB:  PubMed          Journal:  Int J Biol Macromol        ISSN: 0141-8130            Impact factor:   6.953


  1 in total

1.  Reduced binding activity of vaccine serum to omicron receptor-binding domain.

Authors:  Mingzhi Li; Shiqi Weng; Quansheng Wang; Zibing Yang; Xiaoling Wang; Yanjun Yin; Qiuxiang Zhou; Lirong Zhang; Feifei Tao; Yihan Li; Mengle Jia; Lingdi Yang; Xiu Xin; Hanguang Li; Lumei Kang; Yu Wang; Ting Wang; Sha Li; Lingbao Kong
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.